small molecule

LOKELMA

SODIUM ZIRCONIUM CYCLOSILICATE

Loss of exclusivityOctober 2035latest FDA-listed patent expiry
CompanyASTRAZENECA PHARMACEUTICALS LP

Drug detail

Brand nameLOKELMA
Active ingredientSODIUM ZIRCONIUM CYCLOSILICATE
Strength5GM/PACKET
Dosage formFOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalMay 2018
Marketing statusRX

Listed patents

PatentExpiresType
11738044October 2035use U-2312
9592253October 2035substance
10300087October 2035substance
10695365October 2033substance
9913860October 2033substance
8877255October 2033substance
8802152April 2032substance
10335432February 2032use U-2312
8808750February 2032use U-2312
9844567February 2032use U-2312
11406662February 2032substance
10398730February 2032use U-2312
10413569February 2032substance
9861658February 2032use U-2312

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LOKELMA patent cliff — loss of exclusivity October 2035 | CliffBio